Efficacy of Covexir® (Ferula foetida oleo‐gum) treatment in symptomatic improvement of patients with mild to moderate COVID‐19: A randomized, double‐blind, placebo‐controlled trial. (27th July 2022)

• Record Type: Journal Article
• Authors: Hasanpour, Maede; Safari, Hossein; Mohammadpour, Amir Hooshang; Iranshahy, Milad; Dehghan Nayyeri, Mohammad Javad; Farhadi, Faegheh; Emami, Bahareh; Iranshahi, Mehrdad
• Is Part Of: Phytotherapy research. Volume 36:Number 12(2022)
• Page Start: 4504
• Page End: 4515
• Publication Date: 2022-07-27
• Subjects: COVID‐19 -- Ferula foetida -- H2S donors -- medicinal plants -- natural sulfur compounds; Materia medica, Vegetable -- Periodicals; Botany, Medical -- Periodicals; Medicinal plants -- Periodicals; Plant Extracts -- therapeutic use -- Periodicals; Plants, Medicinal -- Periodicals; 581.634
• DOI: 10.1002/ptr.7567
• Languages: English
• ISSNs: 0951-418X

Abstract

Abstract: The SARS‐CoV‐2 COVID‐19 pandemic has emerged as an unprecedented emergency state in healthcare system and global challenge. In recent decade, the function of exogenous H2 S in the treatment of respiratory diseases has been investigated using H2 S‐donor agents. Ferula foetida is a medicinal plant that is traditionally used in respiratory diseases including asthma and viral respiratory diseases. The oleo‐gum of this plant is a rich source of several organic sulfides including thiophenes, disulfides and polysulfide derivatives, which can act as H2 S‐donor agents. The purpose of this study was to investigate the efficacy of Covexir® ( F. foetida oleo‐gum) treatment as a rich source of H2 S‐donor compounds in clinical presentations of patients with COVID‐19. The efficacy of Covexir® was evaluated in a randomized, double‐blind, placebo‐controlled trial in outpatients with COVID‐19. Covexir® could significantly inhibit cough when compared to the placebo group ( p < .01 and p < 001, respectively). Moreover, there was a significant difference ( p < 001) between the two groups in dyspnea symptom at follow‐up interval of 7 day after receiving Covexir®. Furthermore, on days 3 and 7, statistically significant differences were observed in myalgia, anorexia, anosmia, and sense of taste severity between two groups. Our findings revealed that Covexir® was very safe in the treatment of COVID‐19 patients with mild to moderate symptoms and it can be recommended to improve clinical presentations of patients with COVID‐19 such as cough, shortness of breath, myalgia, anorexia, anosmia, and sense of taste.